Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
erenumab
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
pharmacies nationwide
|
| gptkbp:availableIn |
multiple countries
|
| gptkbp:brand |
gptkb:Aimovig
|
| gptkbp:clinicalTrials |
Phase 3
ARISE EVOLVE-1 EVOLVE-2 chronic migraine episodic migraine included in migraine management guidelines |
| gptkbp:community_service |
Aimovig_Support_Program
|
| gptkbp:contraindication |
anxiety
depression fatigue insomnia dry mouth hypersensitivity to erenumab |
| gptkbp:customerFeedback |
generally positive
some report side effects |
| gptkbp:dosageForm |
injection
|
| gptkbp:drugInterdiction |
true
available online monoclonal antibody limited data |
| gptkbp:formulation |
solution for injection
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
provided_by_healthcare_provider
|
| gptkbp:historical_analysis |
ongoing studies
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aimovig
|
| gptkbp:is_monitored_by |
side effects
effectiveness of treatment |
| gptkbp:isRecognizedFor |
children
pregnant women nursing mothers |
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:lastProduced |
2018
|
| gptkbp:launchSite |
once a month
|
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:marineSafety |
available
|
| gptkbp:marketedAs |
gptkb:Aimovig
|
| gptkbp:marketingStrategy |
prescription only
|
| gptkbp:offers |
varies by insurance
|
| gptkbp:packaging |
pre-filled syringe
|
| gptkbp:researchFocus |
chronic migraine treatment
episodic migraine treatment |
| gptkbp:route |
subcutaneous
|
| gptkbp:safetyFeatures |
available on website
|
| gptkbp:sideEffect |
nausea
constipation injection site reactions muscle spasms |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
CGRP receptor antagonist
|
| gptkbp:type |
no
|
| gptkbp:usedFor |
migraine prevention
|